Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Up 0.7 %

Tonix Pharmaceuticals stock opened at $0.19 on Friday. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $22.14. The stock has a market cap of $35.45 million, a PE ratio of 0.00 and a beta of 2.06. The stock has a 50-day moving average price of $0.16 and a 200 day moving average price of $1.05. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.